Does Ticagrelor Reduce Events in Peripheral Artery Disease?

Original Title: Ticagrelor for Prevention of Ischemic Events after Myocardial Infarction in Patients with Peripheral Artery Disease.

Reference: Marc P. Bonaca et al. J Am Coll Cardiol. 2016 Jun 14;67(23):2719-28.

 

ticagrelorPeripheral artery disease is associated with high rates of ischemic and bleeding events in patients with prior myocardial infarction.

This study evaluates the safety and efficacy of ticagrelor on major adverse cardiovascular and limb events in patients with peripheral artery disease and prior myocardial infarction.

The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years before randomization) to ticagrelor 90 mg. every 12 hours, ticagrelor 60 mg. every 12 hours, or placebo (all in addition to low doses of aspirin).

1,143 (5% of total patients) presented peripheral artery disease. Researchers analyzed cardiovascular events (cardiovascular death, MI or stroke) and adverse limb events rates (acute ischemia or the need for ischemia driven peripheral revascularization).

Those in the placebo arm with peripheral artery disease (n=404) had higher rates of major cardiovascular events at 3 years than those without peripheral artery disease (n = 6,663; 19.3% vs. 8.4%; p < 0.001). This difference persisted after adjusting. What is more, those with peripheral artery disease presented higher rates of acute limb ischemia (1.0% vs. 0.1%) and more need for peripheral revascularization (9.15% vs. 0.46%).

The relatively reduced risk with ticagrelor was consistent regardless of peripheral artery disease. In fact, those with intermittent claudication showed better absolute risk reduction (number needed to treat: 25) given the higher absolute risk at baseline.

The absolute excess of TIMI major bleeding was 0.12% (number needed to harm: 834).

The 60 mg. arm saw more benefits as regards cardiovascular mortality and all- cause mortality.

Finally, ticagrelor (considering both doses) reduced limbs events risk (HR: 0.65; CI 95% 0.44 a 0.95; p = 0.026).

Conclusion

Patients with prior acute myocardial infarction and peripheral artery disease presented higher risk of ischemic events. In these patients, ticagrelor reduces major adverse cardiovascular events and major adverse limb events.

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or any ideas here below.

 

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....